Purpose: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is closely associated with Epstein-Barr virus (EBV). To elucidate its pathogenetic role, we examined the expression profiles of EBV-encoded proteins, especially focusing on latent membrane protein 1 (LMP1).
Introduction
Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a rare disease that more frequently develops in East Asia and Central America than in the West (1, 2) . More than 80% of the cases involve the nasal cavity and nasopharynx as initial sites, and approximately 70% of the cases show a localized disease (stage IE and IIE). These cases have recently been controlled by concurrent chemoradiotherapy (3) (4) (5) (6) . Nevertheless, the remaining advanced cases usually present with systemic coagulopathy and multiorgan failure and have poor prognosis (2-4, 7, 8) . In more than 95% of the cases, neoplastic cells possess the Epstein-Barr virus (EBV) genome (1, 4, 8) . In an immunocompetent setting, ENKL is most closely associated with EBV infection among EBVrelated lymphomas, including Hodgkin lymphoma and Burkitt lymphoma (1, 9) .
EBV is a lymphotropic herpes virus, which is carried in more than 90% of worldwide adult populations (9) . EBV entry into the host cell results in lytic or latent infection. In lytic infection, EBV initially expresses the transactivator protein ZEBRA, which induces the lytic gene expression and leads to virion production and host cell lysis (10) . The latent infection is characterized by expression of the latent gene products including EBV nuclear antigen (EBNA) 1, 2, and 3, latent membrane protein (LMP) 1 and 2, EBVencoded small RNA (EBER) 1 and 2, and BamH1 rightward transcripts (10, 11) . After establishment of in vitro infection of B cells, EBV fully expresses these products, and their latency program is referred to as "type III latency" (10) . These latent gene products can alter the infected cell phenotype, resulting in oncogenic transformation of EBVcarrying cells (10, 11) . Of these products, LMP1 is recognized as an oncoprotein, and it elicits the TNF receptor signaling pathway by recruiting TNF receptor-associated factors and other adaptor proteins in the infected cells (10, 11) . LMP1 activates the NF-kB and phosphoinositide 3-kinase/Akt signaling through this pathway (10, 11) . These events play important roles in B-cell immortalization and the transformation of rodent fibroblasts (10, 11) .
Expression of the latent genes in EBV-infected T and natural killer (NK) cells is restricted in EBERs, EBNA1, LMP1, and LMP2 (12, 13) . This program is called "type II latency" and helps EBV-infected T and NK cells to escape from host immune surveillance because EBV-encoded proteins except for LMPs show relatively low immunogenicity (14) . Indeed, representative EBV-associated malignancies such as Hodgkin lymphoma and nasopharyngeal carcinoma (NPC) show "type II latency" (10) . Although ENKL is considered to show type II latency, little is known about its detailed profile and contribution to the clinical and biologic aspects of ENKL (15, 16) .
In this study, we examined the expression profiles of EBVencoded gene products and evaluated its clinicopathologic features in ENKL. EBV seems to be associated with not only tumorigenesis but also the nature of ENKL.
Patients and Methods

Patients and diagnosis
We retrospectively analyzed data from patients with ENKL, who were diagnosed at Juntendo University Hospital (Tokyo, Japan) between August 1996 and June 2010. Clinical presentations of 2 cases were previously reported because of their distinctive clinical and immunophenotypic features (17, 18) . A biopsy and further evaluation were conducted after obtaining written informed consent from each patient. All cases were diagnosed according to the current World Health Organization classification (1).
Although T-cell receptor (TCR) gene rearrangement was not necessarily analyzed in all cases, flow cytometry defined the cases showing surface CD3 þ /CD5 þ and surface
þ immunophenotypes as T-cell and NKcell types, respectively. In addition, immunohistochemistry for TCRb (anti-TCRb, Santa Cruz Biotechnology) was also used to confirm T-cell type ENKL. This study was conducted with the approval of the Institutional Review Board at Juntendo University.
In situ hybridization and immunohistochemistry Latent EBV infection was determined by EBER in situ hybridization (ISH) using EBER PNA probes (Dako) according to the manufacturer's protocol. To detect EBVencoded proteins, paraffin-embedded sections were treated with Tris-EDTA buffer (pH, 9.0) for 40 minutes at 98 C and incubated with primary mouse monoclonal antibodies as follows: CS1-4 (anti-LMP1; Dako), PE-2 (anti-EBNA2; Dako), and BZ-1 (anti-ZEBRA; Dako). As for LMP2A detection, we used 2 rat monoclonal antibodies, 15F9 and 4E11 (Santa Cruz Biotechnology) after treatment with 0.1 mol/L citrate buffer (pH, 6.0) for 7 minutes at 120 C. In addition, immunostaining for phosphorylated forms of RelA and Akt was carried out using rabbit monoclonal antibodies antiphosphorylated RelA (Ser 536; Cell Signaling Technology) and anti-phosphorylated Akt (Thr 308; Santa Cruz Biotechnology), respectively. The antibody signals were enhanced by Envision (Dako) or a Catalyzed Signal Amplification System II (Dako).
Cell lines
To evaluate the association between LMP1 expression and phosphorylation of NF-kB RelA and Akt, 2 ENKLderived cell lines, Hank1 and NK-YS [kindly provided by Dr. Masao Seto, Aichi Cancer Center (Nagoya, Japan) and Dr. Junjiro Tsuchiyama, Kawasaki Medical School (Kurashiki, Japan), respectively] were used (19, 20) . Although Hank1 shows abundant expression of LMP1, the level in NK-YS is low. Another NK cell line, NKL [kindly provided by Dr Michael J Robertson, Indiana University (Bloomington, IN)] was used as an EBV-negative control (21) . These cell lines were maintained in Iscove's Modified Dulbecco's medium (Invitrogen) containing 10% FBS (Invitrogen) and 100 U/mL human interleukin (IL)-2 (a gift from Shionogi, Osaka, Japan). In detection of phosphorylated Akt by Western blot analysis, these cell lines were starved of IL-2 for 48 hours and then treated with or without 500 U/mL IL-2 for 3 hours.
Western blot analysis
Cellular protein was electrophoresed on 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. 
Translational Relevance
Latent membrane protein (LMP1) is a major oncoprotein of Epstein-Barr virus (EBV). We showed a correlation of LMP1 expression with biologic and clinical characteristics in extranodal NK/T-cell lymphoma, nasal type (ENKL), which is closely associated with EBV in immunocompetent patients. Although the expression showed a nonuniform distribution, immunohistochemistry detected LMP1 in more than 70% of the cases. LMP1 positivity had a strong correlation with activation of NFkB RelA and Akt in ENKL. These events may lead to a survival advantage in the neoplastic cells. Nevertheless, LMP1-positive ENKL cases tended to present with a localized disease and clearly showed a favorable outcome. Our observations suggest that LMP1 expression affects the nature of ENKL. EBV may biologically and clinically continue to function in ENKL.
were enhanced using ECL plus (GE Healthcare) according to the manufacturer's protocol. We quantified the expression levels of the 2 phosphorylated forms by comparison with their total protein levels with ImageJ version 1.44 (http:// rsweb.nih.gov/ij/).
RNA interference for LMP1
siRNA duplexes against LMP1 were synthesized by Applied Biosystems (Silencer Select siRNA). The siRNA target sequence to LMP1 mRNA is aacugguggacucuauugguu. A control scrambled siRNA duplex was also purchased from Applied Biosystems. Transfection of siRNA was carried out using Nucleofector I (Lonza) and assayed for silencing 24 and 48 hours after transfection, respectively. Hank1 cells (1 Â 10 6 ) were resuspended in 100 mL of Solution R with 200 nmol/L of each siRNA. Total RNA and whole-cell lysate were extracted from each 2 Â 10 6 cells, respectively. Quantitative Real-time reverse transcriptase PCR analysis was conducted on a CFX96 real-time PCR detection system with SsoFast EvaGreen supermix (Bio-Rad Japan). The primers used for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and LMP1 were designed as previously described (22, 23) and synthesized by Invitrogen. Relative mRNA levels were assessed by normalizing the obtained fluorescence data of LMP1 by those of GAPDH using the DDC t method.
Statistical analysis
The influence of LMP1 expression on clinicopathologic features of ENKL was evaluated by the Fisher exact test. Overall survival (OS) and progression-free survival (PFS) were measured and calculated by the Kaplan-Meier method, and statistical significance was assessed by the log-rank test. All P values were 2-sided, and values less than 0.05 were considered statistically significant. These analyses were conducted with PASW Statistics software version 18 (SPSS Japan).
Results
Morphologic and immunophenotypic features of ENKL
A total of 30 cases were diagnosed as ENKL. Tumor cells frequently showed an angiodestructive growth pattern, and this resulted in infiltrated tissue necrosis (Fig. 1A) . Immunohistochemistry showed that all cases were positive for EBERs, TIA-1, and granzyme B (Table 1 , Fig. 1B-D) . The neoplastic cells consisted of a mixture of small-to mediumsized cells with a round-to-convoluted nuclear shape. This morphologic feature corresponds to the typical pleomorphic type ( Fig. 1E and F) . In contrast, 5 cases had a larger cell size and were described as "large cell" variant ( Fig. 1G and H). Immunophenotypic features are listed in Table 1 . Among the 30 cases, 27 (90.0%) were classified as NK-cell type ENKL, and 3 (10.0%) were T-cell type ENKL. All NKcell type ENKL cases were positive for CD56. In contrast, one of 3 T-cell type ENKL cases was negative for this molecule. As shown previously (18) , one NK-cell type ENKL aberrantly expressed CD20, which is frequently detected in B-cell lymphomas.
Clinical characteristics of 30 cases with ENKL
Patient characteristics are summarized in Table 1 . Among the 30 patients, no one had a past history suggestive of chronic active EBV-associated disease. They consisted of 19 males and 11 females with a median age of 62 years (range, 27-85 years). Reflecting initial manifestations such as nasal obstruction and bleeding, tumors developed from the nasal cavity or nasopharynx in most cases (27 cases, 90.0%). Four cases (13.3%) were initially involved the skin. According to the American Joint Committee on Cancer (AJCC) staging system, 23 cases (76.7%) presented with a localized disease (stages IE and IIE) and 7 (23.3%) had an advanced disease (stage IV). Among the 7 stage IV cases, 3 were accompanied by hemophagocytosis at diagnosis. The clinical characteristics of the present cases were concordant with those from recent reports (6) .
Expression of EBV-associated gene products in ENKL
ISH clearly showed abundant expression of EBERs, indicating that most neoplastic cells are latently infected with EBV. In contrast, immunohistochemistry failed to detect EBNA2 in any cases (Table 1 , Fig. 2A ). Although ENKL is considered to show type II latency, LMP1 was detected only in 22 cases (73.3%). Another LMP, LMP2A, was detected in 12 cases (40.0%). This study therefore first confirmed the expression of LMP2A in a relatively large series of cases. Coexpression of them was observed only in 10 cases (33.3%). Although Hodgkin-Reed-Sternberg cells used as a positive control clearly expressed both proteins, the expression in ENKL showed a nonuniform distribution in the neoplastic cells ( Fig. 2A) . In addition, LMP1-positive cases not necessarily expressed LMP2A ( Fig.  2A ). The result indicates that a small proportion of ENKL cells may enter the lytic cycle.
LMP1 expression and phosphorylation of RelA and Akt in ENKL
In clinical samples, nuclear localization of phosphorylated RelA was more frequently detected in LMP1-positive cases (17 of 18 cases, 94.4%) than in LMP1-negative ones (2 of 7 cases, 28.6%; Table 2 , Fig. 2B ). In addition, phosphorylated Akt was focally positive only in LMP1-positive cases (21 of 22 cases, 95.5%; Table 2 , Fig. 2B ). Correlations between LMP1 positivity and these findings were statistically significant (P ¼ 0.002 and P < 0.001, respectively, the Fisher exact test; Table 2 ).
We further evaluated the correlations in ENKL-derived cell lines. Western blot analysis clearly detected a retarded band of phosphorylated RelA in Hank1 compared with NK-YS and EBV-negative NKL (Fig. 3A) . Phosphorylation of Akt at Thr 308 was more prominent in Hank1 and NKL compared with in NK-YS (Fig. 3B) . This effect was increased in NK-YS and Hank1 cells cultured with abundantly IL-2-containing medium (500 U/mL; Fig. 3B ). In Hank1, LMP1 expression was also upregulated after treatment of IL-2 (Fig. 3B) . Although phosphorylation of Akt is not necessarily mediated only by LMP1, LMP1 expression may influence the effect in Hank1. To find direct evidence of LMP1 on phosphorylation of RelA and Akt, we carried out RNA interference (RNAi) for LMP1 in Hank1 (Fig. 3C) . After 24 hours of knockdown, proportions of phosphorylated RelA and Akt were clearly decreased (Fig. 3D) . Nevertheless, the potencies were weakened after 48 hours of knockdown (Fig. 3D) . Hank1 had an ability to compensate for loss of LMP1. Thus, LMP1 partially engaged in phosphorylation of RelA and Akt in the ENKL-derived cells.
Prognostic factor, therapy, and impact of LMP1 expression on clinical outcome
According to the International Prognostic Index, approximately two thirds of the cases were scored in the low (12 cases, 40.0%) and low-intermediate (7 cases, 23.3%) risk categories. Although therapeutic options were considered in each case, 17 cases with a localized disease (56.7%) received radiation therapy. The applied chemotherapeutic regimens were not uniform but mainly contained methotrexate and L-asparaginase. Autologous and allogeneic stem cell transplantations were conducted in 4 and 2 cases, respectively. We evaluated correlations between LMP1 positivity and these clinical data. Although most parameters associated with prognosis were not statistically significant, LMP1-positive cases tended to show a localized disease (P ¼ 0.060, the Fisher exact test; Table 2 ). With a median follow-up period of 26.7 months (range, 0.2-142.3 months), the 2.5-year OS rate for the present 30 cases was calculated at 58.0% [95% confidence interval (CI), 38.0%-78.0%; Fig. 4A ]. In LMP1-positive and -negative cases, the 2.5-year OS rates were estimated at 78.3% (95% CI, 58.1%-98.5%) and 12.5% (95% CI, 0.0%-40.2%), respectively (Fig. 4B) . Statistical difference was observed in survival between the 2 groups (P ¼ 0.001, log-rank test). Among 20 cases responding to the therapy, 10 cases (7, LMP1 positive; 3 LMP1 negative) relapsed or showed disease progression. Between 2 LMP1-positive cases histologically reexamined, one (case #6) lost LMP1 expression in the recurrent lesion. In 28 cases evaluable for treatment response, PFS was also statistically significant between LMP1-positive and -negative cases (median, 75.9 vs. 15.5 months, P ¼ 0.013, log-rank test; Fig. 4B ). Thus, LMP1-positive ENKL cases showed a favorable clinical outcome compared with LMP1-negative ones.
Discussion
In the present study, most ENKL cases showed a uniform pattern of onset, typical pleomorphic cell morphology, and a similar NK cell immunophenotype. Although ENKL presented as a simple disease entity, immunohistochemistry confirmed heterogeneous expression patterns of LMP1 and LMP2A. The result indicates that expressions of EBV-associated proteins vary among cases. In addition, a small proportion of neoplastic cells seemed to enter the lytic cycle. Namely, EBV can disrupt its latency in ENKL cells. The detection frequency was lower for LMP2A than for LMP1. Fox and colleagues recently reported the existence of a novel LMP2A protein derived from alternatively spliced mRNA in ENKL cells (24) . Besides sensitivity, the 2 antibodies used may fail to detect the protein due to different immunogenicity.
During in vitro EBV infection of NK or T cells, LMP1 is expressed without the presence of EBNA2, which is the main inducer of LMP1 in EBV-infected B cells (10, 12, 13) . We previously showed that LMP1 expression in EBV-infected NK cells was observed after establishment of latent infection (12) . LMP1 expression in ENKL seems to be controlled by the surrounding environment such as cytokines (25) . Although stimulation of IL-10 and IFN-g likely influence LMP1 expression, ENKL cells themselves secrete these cytokines affecting the surrounding cells and may induce tissue necrosis and vascular damage (16, (26) (27) (28) . We assume that the expression of LMP1 in ENKL may be controlled under the dynamic relationship between the neoplastic and surrounding cells.
Although the physiologic functions of LMP1 in Hodgkin lymphoma and NPC are well investigated (10, 11) , the pathogenetic role in ENKL has been not fully evaluated. We confirmed that LMP1 expression in ENKL was correlated with both nuclear localization of RelA and detection of phosphorylated Akt. Indeed, the activation of NF-kB and phosphorylation of Akt in ENKL cells has mainly been discussed in relation to stimulation effects of cytokines such as IL-2 and IL-15 (29, 30) . Although environmental factors may exert a supportive role in the activation of NF-kB and phosphorylation of Akt, RNAi for LMP1 in Hank1 cells confirmed a major effect of LMP1 on these events in ENKL cells. Similar to Hodgkin lymphoma and NPC, LMP1 potentially engages the activation of NF-kB and Akt even in ENKL.
In vitro studies suggest that LMP1-expressing ENKL cells may have a survival advantage compared with LMP1-negative ones. Contrary to this hypothesis, LMP1 expression clinically showed a favorable outcome in ENKL. Because LMP1-positive cases tended to show a localized disease, the clinical stage probably influences the prognosis. Among the LMP1-positive cases, one showed that cytotoxic T-cell infiltration into the lesion, which seemed to be associated with tumor regression (17) . LMP1 has antigenicity and further upregulates expressions of adhesion molecules and surface antigens in the host cells (14, (31) (32) (33) (34) . Although LMP1 may render the cell malignant phenotype, these alterations should be involved in host immune response and may affect the manner of tumor progression. Previous in vitro studies show that cytotoxic T cells against LMP1 can directly kill ENKLderived cell lines (35, 36) . Therefore, LMP1 may have reciprocal effects on the expressing cells, that is, even though LMP1-expressing cells show a malignant phenotype, an extrinsic immune system can eradicate these cells in vivo. In Hodgkin lymphoma, the presence of LMP1 seems to influence its clinical behavior in concert with the patient's age and histology (37, 38) . In addition, LMP1- Days after diagnosis 0 1,000 2,000 3,000 4,000 5,000 Days after diagnosis 0 1,000 2,000 3,000 4,000 5,000
Days after starting treatment Probability of survival Probability of survival Probability of PFS Figure 4 . OS and PFS of the present cases. A, the 2.5-year OS rate for the present 30 cases was calculated as 58.0%. B, between LMP1-positive and -negative cases, the OS and PFS rates were statistically significant (P ¼ 0.001 and 0.013, respectively, log-rank test).
positive NPC is reported to be less prone to relapse, despite its aggressive clinical behavior (39, 40) . Although the impact of LMP1 on clinical outcome remains controversial, we assume that LMP1-positive ENKL cells are prone to targets of cytotoxic T cells, despite their pernicious nature.
In conclusion, we observed nonuniform expression patterns of LMP1 and LMP2A in ENKL clinical samples. LMP1 expression is correlated with phosphorylation of RelA and Akt and potentially has a favorable impact on clinical outcome in ENKL. To address this issue, further prospective evaluation is needed.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. 
